FDA, Industry Unveil Mechanistic Trial Simulation Models
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA partnered with industry to create four trial simulation models for Parkinson's disease, diabetes, depression and measuring cancer progression, which were unveiled at the Jan. 24-25 Drug Industry Association meeting on "Sharing Knowledge To Improve Clinical Drug Development and Regulatory Decisions.